Undifferentiated pleomorphic sarcoma
MONDO:0002142An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate. It is also known as malignant fibrous histiocytoma.
Also known as: MFH, Storiform-pleomorphic MFH, Storiform-pleomorphic fibrous histiocytoma, Storiform-pleomorphic malignant fibrous histiocytoma, UPS, Unclassified Pleomorphic sarcoma (formerly "MFH"), Unclassified Pleomorphic sarcoma (formerly "malignant fibrous histiocytoma"), adult malignant fibrous histiocytoma
2857 clinical trials for this condition and its sub-types, 48 tagged with Undifferentiated pleomorphic sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Undifferentiated pleomorphic sarcoma
-
Can a dual immune antibody plus radiation shrink metastatic sarcoma?
Disease control CompletedResearchers are testing a combination of the experimental antibody MEDI5752 and stereotactic body radiotherapy in people with metastatic soft tissue sarcoma that has spread to the lungs. MEDI5752 targets two immune checkpoints, PD-1 and CTLA-4, and the radiation is aimed at one l…
Phase 1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy boosts chemo against rare sarcomas?
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…
Phase 2 • Sponsor: Alexander Z. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental combo shows promise for rare sarcomas
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine) is safe for people with two rare types of soft tissue sarcoma (leiomyosarcoma and undifferentiated pleomorphic sarcoma). Twenty-five adults with advanced or in…
Phase 1/2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo shows promise for rare cancers
Disease control CompletedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and cyclophosphamide (a chemotherapy)—in 129 people with advanced sarcomas that had spread or could not be removed by surgery. The goal was to see if the combination could shrink tumors or stop them fro…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Phase 3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental drug combo targets Hard-to-Treat sarcomas
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, alone or with the immunotherapy nivolumab, in 245 adults and teens aged 12+ with advanced solid tumors, including sarcomas. The goal was to check safety and see if the drug shrinks tumors. The trial is now complete, and resu…
Phase 1/2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a simple test predict who will respond to this sarcoma drug?
Knowledge-focused CompletedThis study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC